期刊
JOURNAL OF CLINICAL ONCOLOGY
卷 32, 期 16, 页码 1655-1661出版社
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2013.53.1079
关键词
-
类别
资金
- National Institute on Drug Abuse, National Institutes of Health [DA02615, DA06241, DA07242]
- National Cancer Institute [CA08748]
Opioids remain the mainstay of severe pain management in patients with cancer. The hallmark of pain management is individualization of therapy. Although almost all clinically used drugs act through mu opioid receptors, they display subtle but important differences pharmacologically. Furthermore, not all patients respond equally well to all drugs. Evidence suggests that these variable responses among patients have a biologic basis and are likely to involve both biased agonism and the many mu opioid receptor subtypes that have been cloned. (C) 2014 by American Society of Clinical Oncology
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据